Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the
safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of
SHR-A1811 in combination with chemotherapy and/or immunotherapy in HER2-positive
advanced/metastatic gastric/gastroesophageal junction adenocarcinoma patients.
The Phase II study was designed to evaluate the efficacy and safety of SHR-A1811 in
combination with chemotherapy and/or immunotherapy for advanced/metastatic HER2-positive
gastric/gastroesophageal conjunctional adenocarcinoma patients.